Research Analysts Issue Forecasts for IRWD FY2026 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research lowered their FY2026 earnings per share estimates for shares of Ironwood Pharmaceuticals in a report issued on Tuesday, December 10th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.43 per share for the year, down from their previous forecast of $0.44. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same period last year, the firm earned $0.12 EPS. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year.

IRWD has been the topic of several other reports. Leerink Partners began coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective for the company. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Down 3.5 %

IRWD stock opened at $3.56 on Friday. Ironwood Pharmaceuticals has a 12 month low of $3.06 and a 12 month high of $15.70. The firm’s fifty day simple moving average is $4.03 and its 200-day simple moving average is $5.02.

Insider Transactions at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its stake in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares in the last quarter. KBC Group NV boosted its holdings in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. First Dallas Securities Inc. acquired a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at about $73,000. Diversified Trust Co purchased a new stake in Ironwood Pharmaceuticals during the third quarter worth about $52,000. Finally, Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth about $51,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.